- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma, Carcinoma Arising From Cylindroma, Carcinoma Arising From Spiradenoma, Digital Papillary Adenocarcinoma, Endocrine Mucin-Producing Sweat Gland Carcinoma, Extramammary Paget Disease, Extraocular Sebaceous Carcinoma, Hidradenocarcinoma, Malignant Sweat Gland Neoplasm, Merkel Cell Carcinoma, Microcystic Adnexal Carcinoma, NK-Cell Lymphoma, Unclassifiable, Papillary Adenocarcinoma, Porocarcinoma, Primary Cutaneous Mucinous Carcinoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Merkel Cell Carcinoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Skin Squamous Cell Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Signet Ring Cell Adenocarcinoma, Skin Adenoid Cystic Carcinoma, Skin Adnexal Carcinoma, Skin Basal Cell Carcinoma, Skin Basosquamous Cell Carcinoma, Skin Keratoacanthoma, Skin Squamous Cell Carcinoma, Squamoid Eccrine Ductal Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Sweat Gland Carcinoma, Trichilemmal Carcinoma, Vulvar Squamous Cell Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Nivolumab, Positron Emission Mammography, Talimogene Laherparepvec
- Procedure · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 36
- States / cities
- Los Angeles, California • Orange, California • Pasadena, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 380
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Skin Cancer, Non-Melanoma, Skin Cancer Melanoma, Mohs Micrographic Surgery
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer), Non-Small Cell Lung Cancer, MSI-H/dMMR Rectal Cancer, Squamous Cell Carcinoma Mouth, Invasive Mammary Carcinoma, Classic Hodgkin Lymphoma
- Interventions
- Dual-Energy X-ray Absorptiometry (DXA), High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
- Device
- Lead sponsor
- Jessica Mezzanotte Sharpe
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- aldesleukin, ras peptide cancer vaccine, sargramostim, DetoxPC
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma (Skin)
- Interventions
- cisplatin, sorafenib tosylate, tamoxifen citrate, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- San Diego Pacific Oncology & Hematology Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Encinitas, California
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, filgrastim, recombinant interferon alfa, cisplatin, dacarbazine, vinblastine
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 94
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
- Conditions
- Melanoma (Skin)
- Interventions
- bevacizumab, oxaliplatin, sorafenib tosylate
- Biological · Drug
- Lead sponsor
- San Diego Pacific Oncology & Hematology Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Encinitas, California
- Conditions
- Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
- Interventions
- monoclonal antibody Me1-14 F(ab')2
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2001
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Melanoma (Skin)
- Interventions
- NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure
- Biological · Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Melanoma (Skin)
- Interventions
- Detox-B adjuvant, verteporfin
- Biological · Drug
- Lead sponsor
- QLT Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Aventura, Florida • Miami Beach, Florida + 3 more
- Conditions
- Melanoma, Skin
- Interventions
- Scan with elastic scattering spectroscopy device to assess risk of malignancy
- Device
- Lead sponsor
- DermaSensor, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- New Smyrna Beach, Florida • Morehead City, North Carolina
- Conditions
- Melanoma (Skin), Skin Cancer
- Interventions
- Nivolumab, Surgery to Remove Tumor for Growth of TIL, CD137, Cyclophosphamide, Fludarabine, TIL Infusion, Interleukin-2
- Drug · Procedure · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, sargramostim, adjuvant therapy
- Biological · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage IV Non-Small Cell Lung Cancer, Stage IV Skin Melanoma, Melanoma of Unknown Primary
- Interventions
- Pembrolizumab, Stereotactic Radiosurgery
- Biological · Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Skin Lesion, Melanoma (Skin), Mole
- Interventions
- Diagnostic Test
- Other
- Lead sponsor
- Orlucent, Inc
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- Fremont, California • Irvine, California • Menlo Park, California + 3 more
- Conditions
- Kidney Cancer, Melanoma (Skin)
- Interventions
- aldesleukin, recombinant interferon alfa
- Biological
- Lead sponsor
- Hoag Memorial Hospital Presbyterian
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2000
- U.S. locations
- 4
- States / cities
- Newport Beach, California • Bloomington, Indiana • Knoxville, Tennessee + 1 more
- Conditions
- Intraocular Melanoma, Melanoma (Skin)
- Interventions
- mouse gp100 plasmid DNA vaccine, The Dermal PowderMed® devices, intramuscularly (IM injection)
- Biological · Device · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 1 Year to 120 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Melanoma (Skin Cancer), Melanoma Stage Stage IIIB, Melanoma Stage M1, Melanoma Stage IV
- Interventions
- Pembrolizumab, Ipilimumab plus nivolumab
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Stage 0 Skin Melanoma, Stage I Skin Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage II Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage III Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
- Interventions
- Internet-Based Intervention, Questionnaire Administration, Survey Administration
- Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • Charlottesville, Virginia
- Conditions
- Melanoma (Skin)
- Interventions
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 156
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 98 more
- Conditions
- Melanoma (Skin)
- Interventions
- QS21, IFA (incomplete Freund's adjuvant), p946, p946/tet-p, Tet-p
- Biological
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Melanoma (Skin), Sarcoma
- Interventions
- dactinomycin, isolated limb perfusion, melphalan
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Nelfinavir Mesylate, Nivolumab, Pembrolizumab
- Drug · Radiation · Other + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Melanoma (Skin), Intraocular Melanoma
- Interventions
- Xenogeneic Tyrosinase DNA Vaccine, TriGrid Delivery System for Intramuscular Electroporation
- Biological · Device
- Lead sponsor
- Ichor Medical Systems Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York